Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VAR-200 by ZyVersa Therapeutics for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
VAR-200 is under clinical development by ZyVersa Therapeutics and currently in Phase I for Focal Segmental Glomerulosclerosis (FSGS). According to...